TY - JOUR
T1 - Serum adiponectin predicts fracture risk in individuals with type 2 diabetes
T2 - the Fukuoka Diabetes Registry
AU - Komorita, Yuji
AU - Iwase, Masanori
AU - Fujii, Hiroki
AU - Ohkuma, Toshiaki
AU - Ide, Hitoshi
AU - Jodai-Kitamura, Tamaki
AU - Sumi, Akiko
AU - Yoshinari, Masahito
AU - Nakamura, Udai
AU - Kang, Dongchon
AU - Kitazono, Takanari
N1 - Funding Information:
The authors thank Y. Kiyohara, Y. Doi, T. Ninomiya, S. Kanba, S. Kumagai, S. Kaizu, Y. Hirakawa, C. Matsumoto, C. Kitaoka (Kyushu University, Fukuoka, Japan), N. Tsutsu, N. Sasaki (Fukuoka Red Cross Hospital, Fukuoka, Japan), K. Nunoi, Y. Sato, Y. Uchizono, A. Yamauchi, K. Itoh, C. Kono (St Mary’s Hospital, Kurume, Japan), S. Nohara, H. Imoto, K. Amano (Steel Memorial Yawata Hospital, Kitakyushu, Japan), D. Gotoh, T. Himeno, M. Toyonaga (Kyushu Central Hospital, Fukuoka, Japan), N. Shinohara, A. Tsutsumi (Fukuoka Higashi Medical Centre, Koga, Japan), Y. Idewaki, M. Nakano, M. Matsuo, S. Morimoto, T. Hyodo (Hakujyuji Hospital, Fukuoka, Japan), M. Minami (Clinic Minami Masae, Fukuoka, Japan), M. Wada (Wada Miya Naika Clinic, Fukuoka, Japan), Y. Yokomizo (Yokomizo Naika Clinic, Kitakyushu, Japan), M. Kikuchi, Y. Kikuchi (Kikuchi Naika Clinic, Itoshima, Japan), R. Nomiyama (Suzuki Naika Clinic, Fukuoka, Japan), S. Nakamura (Nakamura Naika Clinic, Fukuoka, Japan), K. Tashiro (Oshima Eye Hospital, Fukuoka, Japan), M. Yoshinari (Yoshinari Naika Clinic, Fukuoka, Japan), K. Ichikawa (Fukutsu Naika Clinic, Fukutsu, Japan) and T. Omae (Hisayama Research Institute For Lifestyle Diseases, Fukuoka, Japan). The authors also thank clinical research coordinators, C. Ohba, Y. Ono (Hisayama Research Institute for Lifestyle Diseases, Hisayama, Japan) and K. Sekioka (Kyushu University, Fukuoka, Japan) and those in the administration office, T. Matake (Hisayama Research Institute for Lifestyle Diseases, Hisayama, Japan) and J. Ishimatsu (Kyushu University, Fukuoka, Japan). This work was supported, in part, by the Japan Society for the Promotion of Science KAKENHI (grant numbers 23249037 and 23659353 for MI, 16K00861 for HF) from the Ministry of Education, Culture, Sports, Science and Technology of Japan.
Funding Information:
Funding This work was supported, in part, by the Japan Society for the Promotion of Science KAKENHI (grant numbers 23249037 and 23659353 for MI, 16K00861 for HF) from the Ministry of Education, Culture, Sports, Science and Technology of Japan.
Publisher Copyright:
© 2017, Springer-Verlag GmbH Germany.
PY - 2017/10/1
Y1 - 2017/10/1
N2 - Aims/hypothesis: Serum adiponectin has been reported to impact upon fracture risk in the general population. Although type 2 diabetes is associated with increased fracture risk, it is unclear whether serum adiponectin predicts fractures in individuals with type 2 diabetes. The aim of the study was to prospectively investigate the relationship between serum adiponectin and fracture risk in individuals with type 2 diabetes. Methods: In this study, data was obtained from The Fukuoka Diabetes Registry, a multicentre prospective study designed to investigate the influence of modern treatments on the prognoses of patients with diabetes mellitus. We followed 4869 participants with type 2 diabetes (mean age, 65 years), including 1951 postmenopausal women (defined as self-reported amenorrhea for >1 year) and 2754 men, for a median of 5.3 years. The primary outcomes were fractures at any site and major osteoporotic fractures (MOFs). Results: During the follow-up period, fractures at any site occurred in 682 participants, while MOFs occurred in 277 participants. Age-adjusted HRs (95% CIs) of any fracture and MOFs for 1 SD increment in loge-transformed serum adiponectin were 1.27 (1.15, 1.40) and 1.35 (1.17, 1.55) in postmenopausal women and 1.22 (1.08, 1.38) and 1.40 (1.15, 1.71) in men, respectively. HRs (95% CIs) of MOFs for hyperadiponectinaemia (≥ 20 μg/ml) were 1.72 (1.19, 2.50) in postmenopausal women and 2.19 (1.23, 3.90) in men. The per cent attributable risk of hyperadiponectinaemia for MOFs was as high as being age ≥70 years or female sex. Conclusions/interpretation: Higher serum adiponectin levels were significantly associated with an increased risk of fractures at any site and with an increased risk of MOFs in individuals with type 2 diabetes, including postmenopausal women.
AB - Aims/hypothesis: Serum adiponectin has been reported to impact upon fracture risk in the general population. Although type 2 diabetes is associated with increased fracture risk, it is unclear whether serum adiponectin predicts fractures in individuals with type 2 diabetes. The aim of the study was to prospectively investigate the relationship between serum adiponectin and fracture risk in individuals with type 2 diabetes. Methods: In this study, data was obtained from The Fukuoka Diabetes Registry, a multicentre prospective study designed to investigate the influence of modern treatments on the prognoses of patients with diabetes mellitus. We followed 4869 participants with type 2 diabetes (mean age, 65 years), including 1951 postmenopausal women (defined as self-reported amenorrhea for >1 year) and 2754 men, for a median of 5.3 years. The primary outcomes were fractures at any site and major osteoporotic fractures (MOFs). Results: During the follow-up period, fractures at any site occurred in 682 participants, while MOFs occurred in 277 participants. Age-adjusted HRs (95% CIs) of any fracture and MOFs for 1 SD increment in loge-transformed serum adiponectin were 1.27 (1.15, 1.40) and 1.35 (1.17, 1.55) in postmenopausal women and 1.22 (1.08, 1.38) and 1.40 (1.15, 1.71) in men, respectively. HRs (95% CIs) of MOFs for hyperadiponectinaemia (≥ 20 μg/ml) were 1.72 (1.19, 2.50) in postmenopausal women and 2.19 (1.23, 3.90) in men. The per cent attributable risk of hyperadiponectinaemia for MOFs was as high as being age ≥70 years or female sex. Conclusions/interpretation: Higher serum adiponectin levels were significantly associated with an increased risk of fractures at any site and with an increased risk of MOFs in individuals with type 2 diabetes, including postmenopausal women.
UR - http://www.scopus.com/inward/record.url?scp=85024504103&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85024504103&partnerID=8YFLogxK
U2 - 10.1007/s00125-017-4369-1
DO - 10.1007/s00125-017-4369-1
M3 - Article
C2 - 28721438
AN - SCOPUS:85024504103
SN - 0012-186X
VL - 60
SP - 1922
EP - 1930
JO - Diabetologia
JF - Diabetologia
IS - 10
ER -
